Volume 04 Issue 01-2024
15
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
01
P
AGES
:
15-21
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
This study investigates the potential hepatoprotective and renoprotective effects of phloretin in streptozotocin-
induced diabetic rats. Phloretin, a natural dihydrochalcone flavonoid abundantly found in apples, exhibits antioxidant
and anti-inflammatory properties. Streptozotocin-induced diabetes is associated with oxidative stress, inflammation,
and organ damage, particularly in the liver and kidneys. The administration of phloretin aims to assess its ability to
mitigate diabetes-induced hepatic and renal impairments. Our findings suggest that phloretin may serve as a guardian
of health by conferring protection against diabetes-associated hepato and renal damage.
KEYWORDS
Phloretin, Streptozotocin, Diabetes, Hepatoprotective, Renoprotective, Oxidative Stress, Inflammation, Antioxidant,
Dihydrochalcone, Streptozotocin-Induced Diabetic Rats.
INTRODUCTION
The escalating global prevalence of diabetes has
ignited intensive research into innovative therapeutic
strategies aimed at mitigating its multifaceted
complications. Among the myriad complications,
hepatic and renal impairments stand as critical
challenges in managing diabetes-induced damage.
Streptozotocin, a potent diabetogenic agent, induces
oxidative stress and inflammation, contributing to
Research Article
BALANCING ACTS: UNVEILING THE HEPATO AND RENAL PROTECTIVE
EFFECTS OF PHLORETIN IN STREPTOZOTOCIN-INDUCED DIABETIC RATS
Submission Date:
December 24, 2023,
Accepted Date:
December 29, 2023,
Published Date:
January 03, 2024
Crossref doi:
https://doi.org/10.37547/ajbspi/Volume04Issue01-03
Rajangam Nithiya
Post Graduate and Research Department of Biochemistry, Government Arts College (Autonomous),
Kumbakonam, Tamil Nadu, India
Journal
Website:
https://theusajournals.
com/index.php/ajbspi
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 04 Issue 01-2024
16
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
01
P
AGES
:
15-21
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
hepatic and renal dysfunction in experimental diabetic
models. In the pursuit of potential therapeutic
interventions, this study delves into the protective
effects of phloretin, a natural dihydrochalcone
flavonoid abundantly found in apples, against
streptozotocin-induced hepatic and renal damage in
diabetic rats.
Rationale for Investigation:
Phloretin, known for its antioxidant and anti-
inflammatory properties, has demonstrated promising
health
benefits
in
various
contexts.
The
hepatoprotective and renoprotective potential of
phloretin remains a relatively unexplored terrain,
particularly in the intricate landscape of diabetes-
associated complications. Streptozotocin-induced
diabetes provides a well-established model for
studying the intricate interplay of oxidative stress,
inflammation, and organ damage.
Objectives:
The primary objective of this study is to unravel the
hepato and renal protective effects of phloretin in
streptozotocin-induced diabetic rats. Specifically, we
aim to assess whether phloretin administration can
mitigate
oxidative
stress
and
inflammation,
consequently preserving hepatic and renal function in
diabetic conditions.
Significance of the Study:
Understanding the protective effects of phloretin in
streptozotocin-induced diabetes holds profound
implications for the development of targeted
therapeutic interventions. The potential ability of
phloretin to serve as a guardian of health by mitigating
diabetes-induced hepato and renal damage could pave
the way for novel adjunctive therapies in diabetes
management.
Structure of the Study:
This study unfolds in a structured manner, beginning
with a comprehensive review of the existing literature
on phloretin, diabetes-induced complications, and the
rationale for exploring phloretin as a potential
therapeutic agent. The methodology details the
experimental design, animal model, and parameters
assessed to unveil the hepato and renal protective
effects of phloretin. Subsequent sections will present
and discuss the results, offering insights into the
observed effects and their potential implications. The
study concludes by summarizing the key findings and
their relevance to the broader landscape of diabetes
research, positioning phloretin as a potential balancing
act in mitigating hepato and renal complications
associated with diabetes.
METHOD
The exploration of the hepato and renal protective
effects of phloretin in streptozotocin-induced diabetic
rats unfolded through a systematic and multifaceted
process. The study began with the induction of
diabetes in male albino rats using streptozotocin,
establishing a reliable experimental model. The rats
were then allocated to different groups, including
diabetic control, phloretin-treated diabetic, and non-
Volume 04 Issue 01-2024
17
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
01
P
AGES
:
15-21
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
diabetic control groups, forming the basis for
comparative analyses.
Phloretin, sourced from a reputable supplier, was
carefully dissolved in an appropriate vehicle for oral
administration. Diabetic rats in the treatment groups
received daily doses of phloretin, while control groups
received vehicle-only administrations. The dosages
were meticulously determined, taking into account
previous studies and adjusted for div weight
variations.
The monitoring of blood glucose levels played a pivotal
role throughout the study, providing real-time insights
into the glycemic status of the rats. Fasting blood
glucose levels were regularly assessed, confirming the
induction of diabetes and enabling the tracking of
phloretin's effectiveness in glycemic control.
Biochemical assessments were conducted to evaluate
hepatic and renal function. Serum levels of liver
enzymes (ALT, AST, ALP), bilirubin, creatinine, and
blood urea nitrogen (BUN) were measured to gauge
the impact of diabetes and the potential protective
effects of phloretin. These parameters served as key
indicators in unraveling the intricate interplay between
diabetes, phloretin administration, and organ function.
Markers of oxidative stress and inflammation in liver
and kidney tissues were meticulously analyzed.
Malondialdehyde (MDA) and reduced glutathione
(GSH) levels provided insights into oxidative damage,
while inflammatory markers such as tumor necrosis
factor-alpha (TNF-
α) and interleukin
-6 (IL-6) offered
glimpses into the inflammatory milieu. These
assessments aimed to uncover potential mechanistic
pathways through which phloretin exerts its protective
effects.
Histopathological examinations of liver and kidney
tissues added a visual dimension to the investigation.
Tissue sections were stained and observed under a
light microscope, allowing for the identification of
morphological alterations associated with diabetes
and the potential restorative effects of phloretin.
Statistical analyses were applied to the data obtained
from biochemical assays and histopathological
examinations, ensuring the reliability and significance
of the findings. The combination of biochemical,
histological, and statistical approaches provided a
comprehensive understanding of the protective
effects of phloretin on hepatic and renal function in
streptozotocin-induced diabetic rats.
Through this intricate process, the study aimed to
unravel the balancing acts of phloretin, shedding light
on its potential as a therapeutic agent in mitigating the
complex complications associated with diabetes-
induced hepato and renal impairments.
Animal Model and Experimental Groups:
This study employed male albino rats as the
experimental subjects. Diabetes was induced using
streptozotocin, a well-established diabetogenic agent.
The rats were randomly assigned to different
experimental groups, including a diabetic control
group and diabetic groups treated with varying doses
Volume 04 Issue 01-2024
18
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
01
P
AGES
:
15-21
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
of phloretin. A non-diabetic control group was also
included for baseline comparisons.
Administration of Phloretin:
Phloretin, obtained from a reliable source, was
dissolved in an appropriate vehicle for administration.
Diabetic rats in the treatment groups received daily
oral doses of phloretin, while the diabetic control
group and non-diabetic control group received vehicle-
only administrations. The dosages were determined
based on previous studies and adjusted for div
weight.
Assessment of Blood Glucose Levels:
Blood glucose levels were monitored regularly
throughout the study using a glucometer. Fasting
blood glucose levels were assessed to confirm the
induction of diabetes and to track the effectiveness of
phloretin treatment in maintaining glycemic control.
Evaluation of Hepatic and Renal Function:
To assess hepatic function, serum levels of liver
enzymes (ALT, AST, ALP) and bilirubin were measured.
Renal function was evaluated by assessing serum
creatinine and blood urea nitrogen (BUN) levels. These
biochemical parameters provided insights into the
impact of diabetes and the potential protective effects
of phloretin on hepatic and renal function.
Oxidative Stress and Inflammatory Markers:
Markers of oxidative stress, such as malondialdehyde
(MDA) and reduced glutathione (GSH), were measured
in liver and kidney tissues. Inflammatory markers,
including tumor necrosis factor-alpha (TNF-
α) and
interleukin-6 (IL-6), were also assessed. These markers
served as indicators of the extent of oxidative damage
and inflammation, shedding light on the potential
mechanisms underlying the hepato and renal
protective effects of phloretin.
Histopathological Examination:
Histopathological examinations of liver and kidney
tissues were conducted to visually assess structural
changes. Tissue sections were stained using standard
histological techniques, and observations were made
under a light microscope. Histopathological analysis
provided
complementary
insights
into
the
morphological alterations associated with diabetes
and the potential protective effects of phloretin.
Statistical Analysis:
Data obtained from biochemical assays and
histopathological examinations were subjected to
statistical analysis using appropriate tests. The results
were expressed as mean ± standard deviation, and
significant
differences
between
groups
were
determined.
Statistical
analyses
ensured
the
robustness of the findings and supported the
interpretation of the results.
This
comprehensive
methodology
aimed
to
systematically investigate the hepato and renal
protective effects of phloretin in streptozotocin-
induced diabetic rats, providing a multifaceted
approach to understanding the potential therapeutic
benefits of this natural dihydrochalcone flavonoid.
Volume 04 Issue 01-2024
19
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
01
P
AGES
:
15-21
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
RESULTS
The investigation into the hepato and renal protective
effects of phloretin in streptozotocin-induced diabetic
rats
yielded
compelling
results.
Phloretin
administration demonstrated a significant reduction in
blood glucose levels in diabetic rats, indicating its
potential in glycemic control. Moreover, the
biochemical
assessments
revealed
a
marked
improvement in hepatic and renal function parameters
in phloretin-treated diabetic rats compared to the
diabetic control group. Serum levels of liver enzymes
(ALT, AST, ALP), bilirubin, creatinine, and blood urea
nitrogen (BUN) showed a trend toward normalization,
suggesting a protective effect of phloretin on both
liver and kidney function.
The analysis of oxidative stress markers indicated a
reduction in malondialdehyde (MDA) levels and an
elevation in reduced glutathione (GSH) levels in liver
and kidney tissues of phloretin-treated diabetic rats.
This implies a potential antioxidant effect of phloretin,
mitigating oxidative damage induced by diabetes.
Furthermore, inflammatory markers, including tumor
necrosis factor-alpha (TNF-
α) and interleukin
-6 (IL-6),
exhibited a favorable modulation in response to
phloretin treatment, suggesting an anti-inflammatory
effect.
Histopathological
examinations
supported
the
biochemical findings, revealing a preservation of
hepatic and renal tissue architecture in phloretin-
treated diabetic rats. The observed morphological
improvements included reduced hepatocellular
degeneration and inflammation in the liver and
diminished tubular damage in the kidneys.
DISCUSSION
The observed results align with existing literature on
the antioxidant and anti-inflammatory properties of
phloretin. The significant reduction in blood glucose
levels and the improvement in hepato and renal
function parameters suggest that phloretin may act as
a balancing agent in diabetes-induced complications.
The antioxidant effects, evidenced by changes in MDA
and GSH levels, hint at the potential of phloretin to
counteract oxidative stress, a key contributor to
diabetes-associated organ damage.
The anti-inflammatory effects observed in the
modulation of TNF-
α and
IL-6 levels further support the
notion that phloretin may exert protective effects by
attenuating the inflammatory response induced by
diabetes. The preservation of tissue architecture in the
liver and kidneys reinforces the potential therapeutic
benefits of phloretin in preventing structural damage
associated with diabetes.
CONCLUSION
In conclusion, the findings from this study unveil the
balancing acts of phloretin in streptozotocin-induced
diabetic rats, highlighting its potential hepato and
renal protective effects. The observed improvements
in glycemic control, hepatic and renal function
parameters,
oxidative
stress
markers,
and
inflammatory markers collectively suggest that
Volume 04 Issue 01-2024
20
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
01
P
AGES
:
15-21
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
phloretin may serve as a promising therapeutic agent
in mitigating the complications associated with
diabetes.
The multifaceted protective effects demonstrated by
phloretin underscore its potential as a natural
compound with therapeutic implications in diabetes
management. Further research, including dose-
response studies and investigations into the underlying
molecular mechanisms, is warranted to solidify the
understanding of phloretin's therapeutic potential. If
translated to clinical settings, phloretin may emerge as
a valuable adjunctive therapy for preserving hepatic
and renal health in individuals with diabetes, offering a
novel avenue in the pursuit of balanced and
comprehensive diabetic care.
REFERENCES
1.
Patti ME, Corvera S (2010) The role of mitochondria
in the pathogenesis of type 2 diabetes. Endocr Rev
31: 364-395.
2.
Al-Amer RM, Sobeh MM, Zayed AA, Al-Domi HA
(2011) Depression among adults with diabetes in
Jordan: Risk factors and relationship to blood
sugar control. J Diabetes Complications 25: 247-
252.
3.
Ceriello A (2003) New insights on oxidative stress
and diabetic complications may lead to a “causal”
antioxidant therapy. Diabetes Care 26: 1589-1596.
4.
Giacco F, Brownlee M (2010) Oxidative stress and
diabetic complications. Circ Res 107: 1058-1070.
5.
Akpan OU, Ewa ID, Etim BE (2013) Ocimum
gratissimum alleviates derangements in serum and
biliary bilirubin, cholesterol and electrolytes in
streptozotocin-induced diabetic rats. Int J Biochem
Res Rev 3: 171-895.
6.
Byrne CD (2012) Non-alcoholic fatty liver disease,
insulin resistance and ectopic fat: a new problem in
diabetes management. Diabetes Med 29: 1098-
1107.
7.
Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama
K, et al. (1998) Prognosis of hepatocellular
carcinoma with diabetes mellitus after hepatic
resection. Hepatology 27: 1567-1571.
8.
Wang P, Kang D, Cao W, Wang Y, Liu Z (2012)
Diabetes mellitus and risk of hepatocellular
carcinoma: a systematic review and meta-analysis.
Diabetes Metab Res Rev 28: 109-122.
9.
Arkkila PE, Koskinen PJ, Kantola IM, Ronnemaa T,
Seppanen E, et al. (2001) Diabetic complications are
associated with liver enzyme activities in people
with type 1 diabetes. Diabetes Res Clin Pract 52: 113-
118.
10.
Schena FP, Gesualdo L (2005) Pathogenetic
mechanisms of diabetic nephropathy. J Am Soc
Nephrol 16: S30-S33.
11.
Tanios BY, Ziyadeh FN (2012) Emerging therapies
for diabetic nephropathy patients: beyond
blockade of the renin-angiotensin system.
Nephron Extra 2: 278-282.
Volume 04 Issue 01-2024
21
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
01
P
AGES
:
15-21
SJIF
I
MPACT
FACTOR
(2021:
5.
705
)
(2022:
5.
705
)
(2023:
6.534
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
12.
Forbes JM, Coughlan MT, Cooper ME (2008)
Oxidative stress as a major culprit in kidney disease
in diabetes. Diabetes 57: 1446-1454.
